Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CTRS

- PMLiVE

Ionis and Roche gain PRIME status for Huntingdon’s disease candidate

More good news for Ionis after first drug approval

- PMLiVE

Spinraza keeps Biogen buoyant ahead of Alzheimer’s data

Biotech sees 9% growth ahead of potential landmark announcement

Malthus’ orphans

Firms focusing on small, high-profit niches risk falling into a 200-year-old trap

- PMLiVE

Sanofi’s rare blood disorder drug Cablivi set for European approval

Rare disease drug among notable CHMP recommendations

- PMLiVE

Roche’s MabThera ends drug drought for serious skin disease

As biosimilars seize market share, Roche finds ways to extend blockbuster's revenues

- PMLiVE

Drugs for rare diseases will help propel pharma sales to $1.2trn by 2024; report

Orphan drug sales growth will be 11%+ a year

- PMLiVE

Daily Brief: UK must follow through on Life Sciences Strategy, haemophilia gene therapy latest and more

A rapid round up from the frontline of pharma, biotech and healthcare

- PMLiVE

Despite FDA concerns, Akcea rare disease drug clears FDA panel

FDA now set to deliver final verdict by 30 August

- PMLiVE

Accelerating diagnosis in rare disease

Biopharmaceutical companies can drive effective partnerships and improve outcomes for all stakeholders and patients in the area of rare disease.

- PMLiVE

Vivid Medical Communications Supports the 10th Anniversary of Rare Diseases Day 2018

Vivid Medical Communications – a newly created rare diseases specialist agency and part of the successful Lucid Group of companies – is a proud supporter of Rare Diseases Day 2018.

Lucid Group Communications Limited

Rare Disease Day 2018: Five things you should know about rare diseases.

To help raise awareness for Rare Disease Day, Porterhouse Medical describes five interesting facts about rare diseases

Porterhouse Medical Group

- PMLiVE

EMA hands UniQure orphan status first in Huntington’s

The Dutch biotech expects to file the treatment for approval later this year

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links